Search This Blog

Thursday, August 1, 2024

Ultragenyx Results and Corporate Update

 Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million

Increased 2024 expected total revenue guidance to $530 million to $550 million

https://www.biospace.com/ultragenyx-reports-second-quarter-2024-financial-results-and-corporate-update

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.